We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

Gastroenterology

6

Congresses: Noventure presents its new IBS product Gelsectan® at the 25th UEG week in Barcelona, Spain.

Noventure has participated in the recent 25th UEG week, one of the world’s most important meetings in the field of gastroenterology, which attracts clinicians and basic scientists from all over the world. For the first time the “Gelsectan®” brand was presented at the Noventure stand, now that the medical device is available in its first market, Spain. Gelsectan® belongs to a new class of products defined as “mucosal protectors”, which help restore the normal function of the epithelial barrier in the gut. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.

Read more

New Scientific publication on TASECTAN® DUO

Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25.

Pathogenic microorganisms can adhere to the intestinal mucosa and influence cellular tight-junction function, leading to diarrhea. In an in vitro study, it was compared the protective efficacy of a combination of gelatine tannate plus inactivated probiotic (Tasectan® Duo) with that of other widely used antidiarrheal agents (Diosmectite, Saccharomyces boulardii, and a probiotic mixture). The study results clearly show that the protective efficacy of Tasectan® Duo manifests early and is maintained for 24 h. This effect is quicker and lasts longer that with the other compounds evaluated. These data further reinforce the potential broad utility of Tasectan® Duo in the management of diarrhea of several causes (e.g., infectious gastroenteritis, antibiotic therapy and chemotherapy) in population groups of all ages. Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25. doi: 10.2217/fmb-2016-0195.

Read more

Let's meet in..

2019, Nov 05

CPhI 2019

Read more

2019, Nov 25

euroPLX 71

Read more

2019, Nov 28

PharmaVenue November 2019

Read more